Aducanumab is the only disease-modifying medication currently approved to treat Alzheimer's. This medication is a human antibody, or immunotherapy, that targets the protein beta-amyloid and helps to reduce amyloid plaques, which are brain lesions associated with Alzheimer's.

#Braindisorders #Mentalhealth #Pediatricneurology #braincancer #BrainInjuryandRehabilitation #conference #Neurology #Meeting #NeurologicalDisordersSummit

#Whatsapp:+44 1303 610264

#https://economics.conferenceseries.com/abstract-submission.php

#https://braindisorders.neurologyconference.com/registration.php

#braindisorder@euroannualmeetings.com